Skip to search formSkip to main contentSkip to account menu

FCE-28068

Known as: FCE28068 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate
PurposeIntravenously (i.v.) administered nanomedicines have the potential for tumour targeting due to the enhanced permeability… 
Highly Cited
2009
Highly Cited
2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… 
Review
2009
Review
2009
Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates.
  • B. Říhová
  • Advanced drug delivery reviews
  • 2009
  • Corpus ID: 20423172
Highly Cited
2007
Highly Cited
2007
Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
2007
2007
Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates.
Our past research developed two N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) conjugates that became the… 
Review
2005
Review
2005
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
The last decade has seen successful clinical application of polymer-protein conjugates (e.g. Oncaspar, Neulasta) and promising… 
Highly Cited
2001
Highly Cited
2001
Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License